Kenny De Meirleir

Professor Dr. Kenny L. de Meirleir is a Belgian Internal Medicine doctor who specializes in ME/CFS. He frequently partners with numerous myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) researchers in the EU, UK, US, and Australia to further the understanding of the pathophysiology of ME/CFS. He was an editor of the former Journal of Chronic Fatigue Syndrome. He participated in an earlier clinical trial of Ampligen, an immunomodulator for ME/CFS.

Clinic location
Professor de Meirleir runs a clinic in Brussels, Hummunitas, and also at the Nevada Center for Biomedical Research in Reno, Nevada, in the United States.

Education
(As per bio page at Nevada Center for Biomedical Research)
 * 1970 – 1977 Medical Education, Vrije Universiteit Brussel, Doctor in Medicine (Belgium), Magna cum Laude
 * 1977 – 1982 Internal medicine Residency, Department of Internal Medicine, university Hospital Vrije Universiteit Brussel, under supervision of Prof. Dr. R. Six. Certification in Internal Medicine
 * 1982 – 1984 Resident in Cardiology, Algemeen Ziekenhuis, Vrije Universiteit Brussel, under supervision of Prof. Dr. P. Block, interrupted by military service
 * 1985 Ph.D. in Physiology

Awards

 * Solvay Prize
 * NATO Research Award

CCC and ICC
He is one of the authors of the 2011 case definition, International Consensus Criteria, as well as, the 2003 Canadian Consensus Criteria for Myalgic Encephalomyelitis, published as Myalgic Encephalomyelitis/Chronic Fatigue Syndrome:Clinical Working Case Definition,Diagnostic and Treatment Protocols

Pediatric Case Definition

 * 2006, "A Pediatric Case Definition for Myalgic Encephalomyelitis and Chronic Fatigue Syndrome""'Summary: For a diagnosis of chronic fatigue syndrome (CFS), most researchers use criteria that were developed by Fukuda et al. (1994), with modifications suggested by Reeves et al. (2003). However, this case definition was established for adults rather than children. A Canadian Case Definition (ME/CFS; Myalgic Encephalomyelitis/CFS) has recently been developed, with more specific inclusion criteria (Carruthers et al., 2003). Again, the primary aim of this case definition is to diagnose adult CFS. A significant problem in the literature is the lack of both a pediatric definition of ME/CFS and a reliable instrument to assess it. These deficiencies can lead to criterion variance problems resulting in studies labeling children with a wide variety of symptoms as having ME/CFS. Subsequently, comparisons between articles become more difficult, decreasing the possibility of conducting a meta-analysis. This article presents recommendations developed by the International Association of Chronic Fatigue Syndrome Pediatric Case Definition Working group for a ME/CFS pediatric case definition. It is hoped that this pediatric case definition will lead to more appropriate identification of children and adolescents with ME/CFS.'"

Books

 * 2011, Gezond of gezondigd? by Kenny de Meirleir and Christine Tobback
 * 2006, Pediatric Chronic Fatigue Syndrome by Kenny de Meirleir, [[Neil McGregor], and Elke L.S. Van Hoof]
 * 2002, Chronic Fatigue Syndrome: A Biological Approach Edited by Patrick Englebienne and Kenny De Meirleir
 * 2000, Chronic Fatigue Syndrome: Critical Reviews and Clinical Advances; What Does the Research Say? by Roberto Patarca-Montero and Kenny De Meirleir

Notable studies

 * 2016, Humoral Immunity Profiling of Subjects with Myalgic Encephalomyelitis Using a Random Peptide Microarray Differentiates Cases from Controls with High Specificity and Sensitivity (FULL TEXT)
 * 2016, Genome-wide association analysis identifies genetic variations in subjects with myalgic encephalomyelitis/chronic fatigue syndrome (Schlauch KA, Khaiboullina SF, Kenny de Meirleir, Rawat S, Petereit J, Rizvanov AA, Blatt N, Mijatovic T, Kulick D, Palotás A, Vincent Lombardi).
 * 2013, Plasmacytoid Dendritic Cells in the Duodenum of Individuals Diagnosed with Myalgic Encephalomyelitis Are Uniquely Immunoreactive to Antibodies to Human Endogenous Retroviral Proteins
 * 2009, Detection of Herpesviruses and Parvovirus B19 in Gastric and Intestinal Mucosa of Chronic Fatigue Syndrome Patients Abstract: "Background: Human herpesvirus-6 (HHV-6), Epstein-Barr virus and parvovirus B19 have been suggested as etiological agents of chronic fatigue syndrome but none of these viruses is consistently detected in all patients. However, active viral infections may be localized in specific tissues, and, therefore, are not easily detectable. The aim of this study was to investigate the presence of HHV-6, HHV-7, EBV and parvovirus B19 in the gastro-intestinal tract of CFS patients. Patients and Methods: Using real-time PCR, viral DNA loads were quantified in gastro-intestinal biopsies of 48 CFS patients and 35 controls. Results: High loads of HHV-7 DNA were detected in most CFS and control biopsies. EBV and HHV-6 were detected in 15-30% of all biopsies. Parvovirus B19 DNA was detected in 40% of the patients versus less than 15% of the controls. Conclusion: Parvovirus B19 may be involved in the pathogenesis of CFS, at least for a subset of patients. The gastro-intestinal tract appears as an important reservoir of infection for several potentially pathogenic viruses."
 * 2009, Increased D-Lactic Acid Intestinal Bacteria in Patients with Chronic Fatigue Syndrome
 * 2004, The Fennell Phase Inventory in a Belgian Sample"'Abstract: The present study is a follow-up of the research conducted by Jason, Fennell et al. (1995, 1999, 2000) on a multistage theory for chronic fatigue syndrome (CFS). This multistage model is a very promising method for the evaluation of patients suffering from CFS and could facilitate the appropriate selection of various psychosocial therapies that improve the patient’s ability to cope with their illness. Four predictive factors emerged with moderate to excellent reliability. A Spearman’s rank correlation revealed positive correlations between our four-factor model and the three-factor model identified by Jason et al.(1999). A correlation matrix between the dimensional psychological investigation and the Fennell Phases revealed characteristics as suggested by previous research.  Biological  parameters  varied  over  the  different phases suggesting an important interaction between body and psyche.'"
 * 2001, A definition-based analysis of symptoms in a large cohort of patients with chronic fatigue syndrome.

Wetenschap voor Patiënten - ME/cvs Vereniging

 * 2012, 01. Is ME and/or CFS a disease?/ Is ME en/of CVS een ziekte? - Prof. Dr. K. de Meirleir
 * 2012, 02. Is it possible to diagnose ME/CFS? / Valt ME/CVS re diagnosticeren? - Prof. Dr. K. de Meirleir
 * 2012, 03. Is ME a hereditary condition?/ Is ME een erfelijke aandoening? - Prof. Dr. K. de Meirleir
 * 2012, 04. ME and sleep disorders / ME en slaapproblemen - prof. Dr. K. de Meirleir
 * 2012, 05. ME and Pain / ME en Pijn - prof. Dr. K. de Meirleir
 * 2012, 06. ME and Hormones / ME en Hormonen - prof. Dr. K. de Meirleir
 * 2012, 07. ME, the immune system and several viruses / ME, het immuunsysteem en diverse virussen - prof. Dr. K. de Meirleir
 * 2012, 08. ME, Blood Circulation and the Brain / ME, de bloedsomloop en de hersenen - prof. Dr. K. de Meirleir
 * 2012, 09. ME and gastrointestinal Problems / ME en maag-darmproblemen - prof. Dr. K. de Meirleir
 * 2013, 10. ME, comorbidity and exclusion criteria / ME, comorbiditeit en uitsluitingscriteria - prof. Dr. K. de Meirleir
 * 2013, 11. Twelve Answers to Questions - ME Irigins and Causes / Bestaan en oorzaken ME - prof. Dr. K. de Meirleir
 * 2013, 12. Misdiagnosis, related Diagnosis and Tests / Verkeerde diagnoses, verwante diagnoses en testen - prof. Dr. K. de Meirleir
 * 2013, 13. Sleep, Pain and Nightmares / Slaap, pijn en nachtzweten - prof. Dr. K. de Meirleir
 * 2013, 14. ME and Treatment / Behandeling - prof. Dr. K. de Meirleir
 * 2013, 15. ME, Remedy and Hope / Remedies en hoop - prof. Dr. K. de Meirleir
 * 2013, 16. ME and Low-Dose Naltrexone (LDN) / Low Dose Naltrexone (LDN) - prof. Dr. K. de Meirleir
 * 2013, 17. ME and the Brain / ME en de hersenen -prof. Dr. K. de Meirleir
 * 2013, 18. ME, Th1, Th2 and Th17 / ME, Th1, Th2 en Th17 - prof. Dr. K. de Meirleir
 * 2013, 19. Subgroups of Patients / Subgroepen patienten - prof. Dr. K. de Meirleir
 * 2013, 20. Sense and Nonsense of Tests / Zin en onzin van testen - prof. Dr. K. de Meirleir

Invest in ME Conference Speeches

 * 2011, Speaker at the 6th Invest in ME International ME Conference on Clinical Diagnosis, Treatments and Trials of ME/CFS DVD available
 * 2009, Speaker at the 4th Invest in ME International ME Conference on Research on Extremely Debilitated M.E. Patients Reveals the True Nature of the Disorder DVD available
 * 2007, Speaker at the 2nd Invest in ME International ME Conference on Treatments for ME/CFS Integrative & Complimentary Medicine DVD available

ME/CFS Alert

 * Episode 45 - Interview with Dr. Kenny de Meirleir, Part 4
 * Episode 44 - Interview with Dr. Kenny de Meirleir, Part 3
 * Episode 43 - Interview with Dr. Kenny de Meirleir, Part 2
 * Episode 42 - Interview with Dr. Kenny de Meirleir

IAMECFS Conference

 * 2016, 12th International IACFS/ME Biennial Clinical and Research Conference, Emerging Science and Clinical Care, Paper presentation:A panel of biomarkers accurately identifies CFS/ME patients and contributes to the understanding of the pathophysiology of the disorder

Other

 * 17 April 2010, Professor Kenny De Meirleir on Chronic Fatigue in Perth, Western Australia at Sir Charles Gairdner Hospital

Online presence

 * PubMed
 * Twitter
 * Facebook
 * Website
 * Wikipedia

Learn more

 * 2013, The De Meirleir Experience
 * 2009, Dr. Kenny de Meirleir
 * 2008, Dr. Kenny De Meirleir – Man on the Move for ME/CFS
 * 2007, ME/CFS & Chronic Infection of the Gut – Notes on Dr. Kenny De Meirleir’s Presentation in Perth